On June 30, 2026, Rising received FDA approval for ANDA219565, marking the launch of its newest bioequivalent product which is poised to create significant market competition and impact pricing strategies for the referenced drug. This regulatory milestone allows Rising to capitalize on the patent cliff, effectively broadening its market share and pressuring competitors to adjust their portfolios in response to the influx of an affordable generic alternative.